Latest Sales Growth News

CurveBeam AI reported a robust 40% increase in purchase orders during Q3 FY25 and secured a non-binding A$18 million vendor financing term sheet, positioning the company for cashflow positivity in Q4.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

Canadian Phosphate Limited reported a steady rise in Q1 sales to $534,000, driven by US demand, with a significant capacity expansion at a key customer set to boost Q2 performance. The company also advances exploration and permitting efforts amid shifting North American phosphate dynamics.

Holista Colltech has closed its ASIC penalty chapter with a $900K final payment, raised $1.53 million through convertible notes, and reported a 10.9% year-on-year sales increase driven by its Dietary Supplements division.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.

WA Kaolin Limited has ramped up production with new classifiers, achieving record sales and securing a $7 million capital raise, while expanding its footprint in the Chinese market.

Syrah Resources reports a strategic pause at its Balama graphite mine while advancing production at its Vidalia AAM facility, navigating evolving US trade policies and strong EV-driven demand. The company’s integrated ex-China supply chain and ESG credentials position it for growth despite near-term operational headwinds.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.